Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study.

McInnes IB, Mease PJ, Schett G, Kirkham B, Strand V, Williams N, Fox T, Pricop L, Jugl SM, Gandhi KK; FUTURE 2 Study Group.

Arthritis Res Ther. 2018 Jun 7;20(1):113. doi: 10.1186/s13075-018-1610-3.

2.

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.

Mease P, van der Heijde D, Landewé R, Mpofu S, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Meiser K, Readie A, Pricop L, Abrams K.

Ann Rheum Dis. 2018 Jun;77(6):890-897. doi: 10.1136/annrheumdis-2017-212687. Epub 2018 Mar 17.

3.

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3).

Nash P, Mease PJ, McInnes IB, Rahman P, Ritchlin CT, Blanco R, Dokoupilova E, Andersson M, Kajekar R, Mpofu S, Pricop L; FUTURE 3 study group.

Arthritis Res Ther. 2018 Mar 15;20(1):47. doi: 10.1186/s13075-018-1551-x.

4.

Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.

Pavelka K, Kivitz A, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, Pricop L, Andersson M, Readie A, Porter B.

Arthritis Res Ther. 2017 Dec 22;19(1):285. doi: 10.1186/s13075-017-1490-y.

5.

Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.

McInnes IB, Mease PJ, Ritchlin CT, Rahman P, Gottlieb AB, Kirkham B, Kajekar R, Delicha EM, Pricop L, Mpofu S.

Rheumatology (Oxford). 2017 Nov 1;56(11):1993-2003. doi: 10.1093/rheumatology/kex301.

6.

Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study.

Kavanaugh A, Mease PJ, Reimold AM, Tahir H, Rech J, Hall S, Geusens P, Wang Z, Pricop L, Mpofu S; FUTURE-1 Study Group.

Arthritis Care Res (Hoboken). 2017 Mar;69(3):347-355. doi: 10.1002/acr.23111.

7.

Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1).

Strand V, Mease P, Gossec L, Elkayam O, van den Bosch F, Zuazo J, Pricop L, Mpofu S; FUTURE 1 study group.

Ann Rheum Dis. 2017 Jan;76(1):203-207. doi: 10.1136/annrheumdis-2015-209055. Epub 2016 May 11.

PMID:
27169431
8.

Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis.

van der Heijde D, Landewé RB, Mease PJ, McInnes IB, Conaghan PG, Pricop L, Ligozio G, Richards HB, Mpofu S.

Arthritis Rheumatol. 2016 Aug;68(8):1914-21. doi: 10.1002/art.39685.

9.

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.

Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewé R, Nash P, Pricop L, Yuan J, Richards HB, Mpofu S; FUTURE 1 Study Group.

N Engl J Med. 2015 Oct;373(14):1329-39. doi: 10.1056/NEJMoa1412679.

10.

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.

McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S; FUTURE 2 Study Group.

Lancet. 2015 Sep 19;386(9999):1137-46. doi: 10.1016/S0140-6736(15)61134-5. Epub 2015 Jun 28.

PMID:
26135703
11.

Cardiac and inflammatory biomarkers and in-hospital mortality in older medical patients.

Comba M, Fonte G, Isaia G, Pricop L, Sciarrillo I, Michelis G, Bo M.

J Am Med Dir Assoc. 2014 Jan;15(1):68-72. doi: 10.1016/j.jamda.2013.10.013. Epub 2013 Dec 4.

PMID:
24314700
12.

Correlation of 18F-FDG PET/CT assessments with disease activity and markers of inflammation in patients with early rheumatoid arthritis following the initiation of combination therapy with triple oral antirheumatic drugs.

Roivainen A, Hautaniemi S, Möttönen T, Nuutila P, Oikonen V, Parkkola R, Pricop L, Ress R, Seneca N, Seppänen M, Yli-Kerttula T.

Eur J Nucl Med Mol Imaging. 2013 Feb;40(3):403-10. doi: 10.1007/s00259-012-2282-x. Epub 2012 Nov 15.

PMID:
23229747
13.

Determinants of recourse to hospital treatment in the elderly.

Sona A, Maggiani G, Astengo M, Comba M, Chiusano V, Isaia G, Merlo C, Pricop L, Quagliotti E, Moiraghi C, Fonte G, Bo M.

Eur J Public Health. 2012 Feb;22(1):76-80. doi: 10.1093/eurpub/ckr008. Epub 2011 Mar 31.

14.

Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway.

Jacob N, Yang H, Pricop L, Liu Y, Gao X, Zheng SG, Wang J, Gao HX, Putterman C, Koss MN, Stohl W, Jacob CO.

J Immunol. 2009 Feb 15;182(4):2532-41. doi: 10.4049/jimmunol.0802948.

15.

High-sensitivity C-reactive protein is not independently associated with peripheral subclinical atherosclerosis.

Bo M, Corsinovi L, Brescianini A, Sona A, Astengo M, Dumitrache R, Ferrio MF, Pricop L, Fonte G.

Angiology. 2009 Feb-Mar;60(1):12-20. doi: 10.1177/0003319708322387. Epub 2008 Oct 7.

PMID:
18840622
16.

Global T cell dysregulation in non-autoimmune-prone mice promotes rapid development of BAFF-independent, systemic lupus erythematosus-like autoimmunity.

Stohl W, Jacob N, Quinn WJ 3rd, Cancro MP, Gao H, Putterman C, Gao X, Pricop L, Koss MN.

J Immunol. 2008 Jul 1;181(1):833-41.

17.

Infliximab treatment shifts the balance between stimulatory and inhibitory Fcgamma receptor type II isoforms on neutrophils in patients with rheumatoid arthritis.

Belostocki K, Pricop L, Redecha PB, Aydin A, Leff L, Harrison MJ, Salmon JE.

Arthritis Rheum. 2008 Feb;58(2):384-8. doi: 10.1002/art.23200.

18.

Regulated expression of FcgammaR in human dendritic cells controls cross-presentation of antigen-antibody complexes.

Liu Y, Gao X, Masuda E, Redecha PB, Blank MC, Pricop L.

J Immunol. 2006 Dec 15;177(12):8440-7.

19.
20.

Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF.

Jacob CO, Pricop L, Putterman C, Koss MN, Liu Y, Kollaros M, Bixler SA, Ambrose CM, Scott ML, Stohl W.

J Immunol. 2006 Aug 15;177(4):2671-80.

21.

FcgammaRIIa is a target for modulation by TNFalpha in human neutrophils.

Belostocki K, Park MS, Redecha PB, Masuda E, Salmon JE, Pricop L.

Clin Immunol. 2005 Oct;117(1):78-86.

PMID:
16084773
22.

Decreased transcription of the human FCGR2B gene mediated by the -343 G/C promoter polymorphism and association with systemic lupus erythematosus.

Blank MC, Stefanescu RN, Masuda E, Marti F, King PD, Redecha PB, Wurzburger RJ, Peterson MG, Tanaka S, Pricop L.

Hum Genet. 2005 Jul;117(2-3):220-7. Epub 2005 May 14.

PMID:
15895258
23.

Cytokine-mediated regulation of activating and inhibitory Fc gamma receptors in human monocytes.

Liu Y, Masuda E, Blank MC, Kirou KA, Gao X, Park MS, Pricop L.

J Leukoc Biol. 2005 May;77(5):767-76. Epub 2005 Feb 9.

PMID:
15703199
24.

Inhibitory Fc gamma receptors: from gene to disease.

Stefanescu RN, Olferiev M, Liu Y, Pricop L.

J Clin Immunol. 2004 Jul;24(4):315-26. Review.

PMID:
15163888
25.

Inhibition of interleukin 10 signaling after Fc receptor ligation and during rheumatoid arthritis.

Ji JD, Tassiulas I, Park-Min KH, Aydin A, Mecklenbrauker I, Tarakhovsky A, Pricop L, Salmon JE, Ivashkiv LB.

J Exp Med. 2003 Jun 2;197(11):1573-83.

26.
27.

Redox regulation of Fcgamma receptor-mediated phagocytosis: implications for host defense and tissue injury.

Pricop L, Salmon JE.

Antioxid Redox Signal. 2002 Feb;4(1):85-95. Review.

PMID:
11970846
28.

Human receptors for immunoglobulin G: key elements in the pathogenesis of rheumatic disease.

Salmon JE, Pricop L.

Arthritis Rheum. 2001 Apr;44(4):739-50. Review.

29.

Differential modulation of stimulatory and inhibitory Fc gamma receptors on human monocytes by Th1 and Th2 cytokines.

Pricop L, Redecha P, Teillaud JL, Frey J, Fridman WH, Sautès-Fridman C, Salmon JE.

J Immunol. 2001 Jan 1;166(1):531-7.

30.

Reactive oxygen intermediates enhance Fc gamma receptor signaling and amplify phagocytic capacity.

Pricop L, Gokhale J, Redecha P, Ng SC, Salmon JE.

J Immunol. 1999 Jun 15;162(12):7041-8.

31.

A naturally occurring mutation in Fc gamma RIIA: a Q to K127 change confers unique IgG binding properties to the R131 allelic form of the receptor.

Norris CF, Pricop L, Millard SS, Taylor SM, Surrey S, Schwartz E, Salmon JE, McKenzie SE.

Blood. 1998 Jan 15;91(2):656-62.

32.
33.

V lambda-light chain genes reconstitute immune responses to defined carbohydrate antigens or haptens by utilizing different VH genes.

Bot A, Nangpal A, Pricop L, Bogen B, Kaushik A, Bona CA.

Mol Immunol. 1996 Dec;33(17-18):1359-68.

PMID:
9171895
34.

Repertoires of antigen receptors in Tdt congenitally deficient mice.

Komori T, Pricop L, Hatakeyama A, Bona CA, Alt FW.

Int Rev Immunol. 1996;13(4):317-25. Review.

PMID:
8884428
35.

Analysis of lambda repertoire in kappa-deficient mice.

Pricop L, Hatakeyama A, Isobe H, Bona C.

Clin Immunol Immunopathol. 1995 Sep;76(3 Pt 2):S179-87. Review. No abstract available.

PMID:
7554465
36.

Antibody response against poly (Glu60Ala30Tyr10) terpolymer and bacterial levan in kappa-deficient mice.

Pricop L, Hatakeyama A, Moran T, Bona C.

Eur J Immunol. 1995 Apr;25(4):1039-43.

PMID:
7737274
37.

Study of self reactive antibodies in kappa-light chain deficient mice.

Hatakeyama A, Pricop L, Kuppuswamy, Kasturi N, Bona CA.

Autoimmunity. 1995;20(2):113-20.

PMID:
7578867
38.

Antibody response elicited by T-dependent and T-independent antigens in gene targeted kappa-deficient mice.

Pricop L, Brumeanu T, Elahi E, Moran T, Wang BS, Troustine M, Huszar D, Alt F, Bona C.

Int Immunol. 1994 Dec;6(12):1839-47.

PMID:
7535094
39.

Expression and function of CD7 molecule on human natural killer cells.

Rabinowich H, Pricop L, Herberman RB, Whiteside TL.

J Immunol. 1994 Jan 15;152(2):517-26.

PMID:
7506726
40.
41.

Expression of Fc mu receptors on human natural killer cells.

Pricop L, Galatiuc C, Manciulea M, DeLeo A, Sulica A, Herberman RB, Whiteside TL.

Clin Immunol Immunopathol. 1991 Jun;59(3):355-67.

PMID:
2029790
42.

Inhibition of human natural killer cell activity by polyclonal IgM.

Manciulea M, Pricop L, Sulica A, Herberman RB.

Mol Immunol. 1989 Dec;26(12):1087-93.

PMID:
2633044
43.

[Cephalic duodenopancreatectomy in a case of an unusual indication].

Dolinescu C, Diaconu C, Pricop L, Scripcaru L.

Rev Med Chir Soc Med Nat Iasi. 1984 Jul-Sep;88(3):555-7. Romanian. No abstract available.

PMID:
6545456
44.

[Acid-base and oxidation-reduction equilibrium in cancer].

Iancu I, Serban F, Busuioc A, Cernătescu D, Ghiorghiţă N, Pricop L, Iacobovici A, Sibi M.

Rev Med Chir Soc Med Nat Iasi. 1984 Jul-Sep;88(3):525-9. Romanian. No abstract available.

PMID:
6545451
45.

[Personal experience in thymus surgery].

Dolinescu C, Diaconescu M, Răileanu R, Pleşa C, Dragomir C, Frunzăreanu N, Vasile V, Burcoveanu C, Pricop L, Untura A, et al.

Rev Med Chir Soc Med Nat Iasi. 1983 Jul-Sep;87(3):411-7. Romanian. No abstract available.

PMID:
6676854
46.

[Parathyroid adenoma and renal lithiasis].

Vexler L, Andrei A, Cordun-Tărăbuţă G, Pricop L.

Chirurgia (Bucur). 1974 Jan;23(1):9-14. Romanian. No abstract available.

PMID:
4819820
47.

[Action of glucagon on blood sugar, urea and electrolytes (Na,K,Cl,P,Ca) and urinary eliminations in patients with cardiac insufficiency].

Tacu V, Casetti M, Rucinski S, Ababei V, Gheorghiu A, Pricop L, Platon M.

Rev Med Chir Soc Med Nat Iasi. 1973 Oct-Dec;77(4):707-14. Romanian. No abstract available.

PMID:
4781124

Supplemental Content

Loading ...
Support Center